Indivior Pharmaceuticals, Inc. (SUPN) Operating Margin
- Operating margin · 12 months: Value 31.63%; Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | 31.63% | Operating income / revenue. Period ending 2026-06-30. $421.00M ÷ $1.33B × 100 ≈ 31.63% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | 421.00M USD | Operating Income (Loss) |
| Revenue | 1.33B USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | 240.00M USD | Cost of Goods and Services Sold |
| Research and development | (m) | |
| Selling, general and administration | 588.00M USD | Selling, General and Administrative Expense |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $421.00M | $1.33B | $240.00M | (m) | $588.00M | 31.63% |
| 2026-03-31 | $333.00M | $1.29B | $242.00M | (m) | $625.00M | 25.81% |
| 2025-12-31 | $262.00M | $1.24B | $246.00M | (m) | $634.00M | 21.15% |
| 2025-09-30 | $227.00M | $1.18B | $227.00M | (m) | $620.00M | 19.24% |
| 2025-06-30 | $219.00M | $1.17B | $210.00M | (m) | $607.00M | 18.67% |
| 2025-03-31 | $29.00M | $1.17B | $237.00M | (m) | $601.00M | 2.48% |
| 2024-12-31 | $32.00M | $1.19B | $231.00M | (m) | $618.00M | 2.69% |
| 2024-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | $-156.00M | $1.09B | $174.00M | (m) | $569.00M | -14.27% |
| 2022-12-31 | $-81.00M | $901.00M | $151.00M | (m) | $469.00M | -8.99% |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |